Momentum Builds for ALX Oncology and Delta Apparel
- October 03rd, 2023
- 644 views
Shares of ALX Oncology Holdings Inc. (Nasdaq: ALXO) surged by more than 20% in after-hours trading following the announcement that it will unveil interim Phase 2 ASPEN-06 clinical trial results of evorpacept, aimed at treating advanced HER2-positive gastric cancer, on Tuesday, October 3.
$ALXO was trading at $5.90, marking a substantial increase of $1.09 (+22.66%) during the extended session.
In unrelated news, Delta Apparel, Inc. (NYSE American: DLA) revealed that it has received an unsolicited offer for its Salt Life business unit. The company's Board of Directors has enlisted Baird as its financial advisor for this development. It's important to note that the timing, terms, or structure of any potential transaction, as well as the likelihood of a transaction occurring, remain uncertain.
In after-hours, $DLA was trading at $7.89, up $1.30 (+19.73%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login